Compare Ascendis Pharma A/S (ASND) vs Core Scientific Inc (CORZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Core Scientific Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Core Scientific Inc trades at $22.93 (market cap $7.47B). The key difference: Ascendis Pharma A/S is far larger — about 2.4× Core Scientific Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Core Scientific Inc nearer its low. Which is the better fit depends on your goals.
| ASND | CORZ | |
|---|---|---|
Market Cap | $17.74B | $7.47B |
Sector | Health | Technology |
52-Week High | $277.18 | $29.16 |
52-Week Low | $163.32 | $12.51 |
Enterprise Value | $18.11B | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CORZ trades at $23.49, down 1.05% on the day, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue growth driven by AI colocation, yet missed EPS estimates. Strong analyst support exists with 19 buy ratings and a $34.17 consensus target, indicating 45% upside potential.
Outlook remains optimistic due to strategic pivot to AI infrastructure, though significant risks include persistent losses, high cash burn, and execution challenges in scaling data center operations amid competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →
